{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T20:19:37Z","timestamp":1785529177012,"version":"3.56.0"},"reference-count":31,"publisher":"American Society for Microbiology","issue":"9","license":[{"start":{"date-parts":[[2014,9,1]],"date-time":"2014-09-01T00:00:00Z","timestamp":1409529600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2014,9]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n          <jats:p>\n            Ceftolozane-tazobactam (TOL-TAZ) is a novel antibacterial with activity against\n            <jats:named-content xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" content-type=\"genus-species\" xlink:type=\"simple\">Pseudomonas aeruginosa<\/jats:named-content>\n            and other common Gram-negative pathogens, including extended-spectrum \u03b2-lactamase (ESBL)-producing\n            <jats:named-content xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" content-type=\"genus-species\" xlink:type=\"simple\">Enterobacteriaceae<\/jats:named-content>\n            , that are associated with complicated intra-abdominal infections (cIAIs). This prospective, double-blind, randomized, multicenter, phase II trial assessed patient clinical and microbiological responses to and the safety of TOL-TAZ plus metronidazole compared with those of meropenem. Hospitalized adults with cIAIs that required surgical intervention were randomized (2:1) to receive intravenous (i.v.) TOL-TAZ (1.5 g [containing 1,000 mg TOL and 500 mg TAZ] every 8 h [q8h]) with or without i.v. metronidazole (500 mg q8h) or i.v. meropenem (1 g q8h) for 4 to 7 days. The primary endpoint was the clinical response at the test-of-cure visit in the microbiologically modified intent-to-treat (mMITT) and microbiologically evaluable (ME) populations. Secondary measures included the patients' microbiological response and safety. In total, 82 patients received TOL-TAZ (90.2% with metronidazole), and 39 received meropenem. For the mMITT population, clinical cure was seen in 83.6% of the patients (51\/61; 95% confidence interval [CI], 71.9 to 91.8) who received TOL-TAZ and 96.0% of the patients (24\/25; 95% CI, 79.6 to 99.9) who received meropenem (difference, \u221212.4%; 95% CI, \u221234.9% to 11.1%); in the ME population, clinical cure was seen in 88.7% and 95.8% of the patients (difference, \u22127.1%; 95% CI, \u221230.7% to 16.9%) who received TOL-TAZ and meropenem, respectively. TOL-TAZ demonstrated microbiological success against\n            <jats:named-content xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" content-type=\"genus-species\" xlink:type=\"simple\">Escherichia coli<\/jats:named-content>\n            (89.5%),\n            <jats:named-content xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" content-type=\"genus-species\" xlink:type=\"simple\">Klebsiella pneumoniae<\/jats:named-content>\n            (100%), and\n            <jats:named-content xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" content-type=\"genus-species\" xlink:type=\"simple\">P. aeruginosa<\/jats:named-content>\n            (100%). The adverse event rates were similar in the groups (50.0% with TOL-TAZ and 48.8% with meropenem). TOL-TAZ in combination with metronidazole was well tolerated and resulted in clinical and microbiological success rates supportive of further clinical development in patients with cIAIs. (This study has been registered at ClinicalTrials.gov under registration no. NCT01147640.)\n          <\/jats:p>","DOI":"10.1128\/aac.00049-14","type":"journal-article","created":{"date-parts":[[2014,7,1]],"date-time":"2014-07-01T14:43:52Z","timestamp":1404225832000},"page":"5350-5357","update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":96,"title":["Multicenter, Double-Blind, Randomized, Phase II Trial To Assess the Safety and Efficacy of Ceftolozane-Tazobactam plus Metronidazole Compared with Meropenem in Adult Patients with Complicated Intra-Abdominal Infections"],"prefix":"10.1128","volume":"58","author":[{"given":"Christopher","family":"Lucasti","sequence":"first","affiliation":[{"name":"South Jersey Infectious Disease, Somers Point, New Jersey, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ellie","family":"Hershberger","sequence":"additional","affiliation":[{"name":"Cubist Pharmaceuticals, Lexington, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Miller","sequence":"additional","affiliation":[{"name":"Cubist Pharmaceuticals, Lexington, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Yankelev","sequence":"additional","affiliation":[{"name":"Cubist Pharmaceuticals, Lexington, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judith","family":"Steenbergen","sequence":"additional","affiliation":[{"name":"Cubist Pharmaceuticals, Lexington, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian","family":"Friedland","sequence":"additional","affiliation":[{"name":"Cubist Pharmaceuticals, Lexington, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Solomkin","sequence":"additional","affiliation":[{"name":"University of Cincinnati College of Medicine, Cincinnati, Ohio, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1089\/sur.2009.9930"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.diagmicrobio.2013.02.031"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.00040-09"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.14.4.933-951.2001"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10096-010-1066-0"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00070-11"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1469-0691.2009.03115.x"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jinf.2013.09.001"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01737-10"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.diagmicrobio.2011.02.004"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkq248"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01802-13"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01404-13"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01104-09"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2007.05.019"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01590-12"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02253-13"},{"key":"e_1_3_2_19_2","volume-title":"53rd Annu. Intersci. Conf. Antimicrob. Agents Chemother.","author":"Lucasti C","year":"2013","unstructured":"LucastiCHershbergerEMillerBYankelevSSteenbergenJFriedlandISolomkin. 2013. A multicenter, double-blind, randomized, phase 2 study to assess the safety and efficacy of ceftolozane\/tazobactam (TOL\/TAZ) plus metronidazole (MTZ) compared to meropenem (MER) in adult patients with complicated intra-abdominal infections (cIAI), poster K-1709. 53rd Annu. Intersci. Conf. Antimicrob. Agents Chemother., 10\u201313 September 2013, Denver, CO."},{"key":"e_1_3_2_20_2","volume-title":"Merrem i.v. prescribing information","author":"AstraZeneca Pharmaceuticals","year":"2013","unstructured":"AstraZeneca Pharmaceuticals. 2013. Merrem i.v. prescribing information. AstraZeneca Pharmaceuticals LP, Wilmington, DE. http:\/\/www1.astrazeneca-us.com\/pi\/merremiv.pdf."},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.06349-11"},{"key":"e_1_3_2_22_2","volume-title":"21st Eur. Congr. Clin. Microbiology and Infectious Diseases and 27th International Congress of Chemother.","author":"Hershberger E","year":"2011","unstructured":"HershbergerEMouksassiMSteenbergenJBenzigerDFenneteauFMarierJFFriedlandI. 2011. CXA-101\/tazobactam probability of target attainment using population pharmacokinetic analysis, poster P1520. 21st Eur. Congr. Clin. Microbiology and Infectious Diseases and 27th International Congress of Chemother., Milan, Italy, 7\u201310 May 2011."},{"key":"e_1_3_2_23_2","volume-title":"Performance standards for antimicrobial susceptibility testing, 15th informational supplement. M100-S20","author":"Clinical and Laboratory Standards Institute","year":"2010","unstructured":"Clinical and Laboratory Standards Institute. 2010. Performance standards for antimicrobial susceptibility testing, 15th informational supplement. M100-S20. Clinical and Laboratory Standards Institute, Wayne, PA."},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.1093\/biomet\/26.4.404"},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2008.04.019"},{"key":"e_1_3_2_26_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dks523"},{"key":"e_1_3_2_27_2","doi-asserted-by":"publisher","DOI":"10.1089\/sur.2011.048"},{"key":"e_1_3_2_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2012.10.014"},{"key":"e_1_3_2_29_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cir790"},{"key":"e_1_3_2_30_2","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.18.4.657-686.2005"},{"key":"e_1_3_2_31_2","doi-asserted-by":"publisher","DOI":"10.1086\/431676"},{"key":"e_1_3_2_32_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.SLA.0000048551.32606.73"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.00049-14","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.00049-14","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T22:47:56Z","timestamp":1645483676000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.00049-14"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,9]]},"references-count":31,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2014,9]]}},"alternative-id":["10.1128\/AAC.00049-14"],"URL":"https:\/\/doi.org\/10.1128\/aac.00049-14","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,9]]},"assertion":[{"value":"2014-01-10","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2014-06-21","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2014-08-14","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}